- STAT+: Triple hormone receptors, a monthly obesity drug, and a bittersweet endingYou're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference in New Orleans.STAT · 1mo ago↗ source
- STAT+: Lilly shares safety, tolerability data on its next-gen obesity drugEli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on Saturday.STAT · 1mo ago↗ source
- STAT+: Detailed data show Pfizer’s monthly obesity drug continues to show potentialDetailed data from a midstage study offered further evidence that the obesity drug Pfizer acquired from the biotech Metsera could be dosed monthly.STAT · 1mo ago